One of the qualms about GLP1s is that they involve a weekly injection, and some people do not like needles
Personalized medication options increase success through control and customization
What do clinicians, the FDA and investors view as success in this space
Supplementary Table 1), and in people of European ancestry 11 (BMI % = 12.1% in Europeans versus 10.6% in non-Europeans
Klil-Drori, A

DOI: Published online: August 18, 2021 1 Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, College of Medicine, Rochester, MN, USA 2 Department of Neurology, Mayo Clinic, College of Medicine, Rochester, MN, USA 3 Department of Psychiatry and Psychology, Mayo Clinic, College of Medicine, Rochester, MN, USA 4 Department of Neuroscience Program, Mayo Clinic, College of Medicine, Rochester, MN, USA Corresponding author: Doo-Sup Choi, PhD Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, College of Medicine, Rochester, 200 1st SW, MN 55905, USA / Tel: +1-507-284-5602 / Fax: +1-507-266-0824 / E-mail: [email protected] Copyright 2021 The Korean Movement Disorder Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited